|
 
Last update: |
 |
|
|
10-Dec-2008
|
 |
|
|
Arch Hellen Med, 25(5), September-October 2008, 634-636 SHORT COMMUNICATION First-time use of bevacizumab for metastatic hepatocellular carcinoma in a HIV/HBV coinfected patient. I.G. BARABOUTIS,1 G. CHARITSIS,2 V. PAPASTAMOPOULOS,1 L.É. LEKAKIS,1 M.M. VASLAMATZIS,3 A.T. SKOUTELIS1,2 |
A case of a HIV-1 infected patient with history of chronic hepatitis B and chronic alcohol use without cirrhosis, who presented with aggressive hepatocellular carcinoma (HCC) with multiple metastasis is presented. Systemic chemotherapy combined with use of bevacizumab (anti-VEGF monoclonal antibody) was without effect and the patient succumbed to his disease within weeks. Relatively recent data indicate that HCC may be extremely aggressive in HIV/HBV or HIV/HCV coinfected patients with younger age at presentation, shorter evolution time, a more advanced stage at presentation with higher rates of extrahepatic-extranodal metastases and, finally, a reduced survival rate as compared with HIV-negative patients. To our knowledge, this is the first report in the English literature of bevacizumab use for metastatic hepatocellular carcinoma in HIV infected patients.
Key words: Anti-VEGF, Bevacizumab, HIV/HBV coinfection, Metastatic hepatocellular carcinoma.
